Organogenesis Holdings Inc. ORGO 深 滬
已收盤 10-24 16:00:00 美东时间
4.26
+0.150
+3.65%
華盛通- 最 高4.39
- 今 開4.18
- 成交量 44.63万股
- 最 低 4.131
- 昨 收 4.11
- 總市值 5.41亿
- 52周最高 6.71
- 市盈率 靜 655.38
- 換手率 0.35%
- 52周最低 2.6101
- 委 比 -98.10%
- 總股本 1.27亿
- 歷史最高 310.90
- 量 比 1.15
- 振 幅 6.30%
- 歷史最低 1.795
- 每 手 1
- 風險率 0.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025
Organogenesis Holdings Inc. (Nasdaq: ORGO) announced it will report its third-quarter FY 2025 financial results on November 6th after market close. A conference call and webcast will be held at 5:00 p.m. ET that day to discuss the results and provide a corporate update. Participants can join via webcast at [https://investors.organogenesis.com](https://investors.organogenesis.com) or by dialing 800-715-9871 (646-307-1963 international) with access...
10-01 20:05
美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
09-29 09:15
Why Is Organogenesis Stock Trading Lower Friday?
Organogenesis Holdings Inc. (NASDAQ: ORGO) shared topline data on Thursday from the second Phase 3 randomized controlled trial (RCT) of ReNu, a cryopreserved amniotic suspension allograft (ASA) for the management of symptoms associated with
09-26 23:24
Organogenesis Announces That The Second Phase 3 Randomized Controlled Trial Of ReNu Did Not Achieve Statistical Significance For Its Primary Endpoint, Despite The ReNu Results Demonstrating A Numerical Improvement In Baseline Pain Reduction Over The First Phase 3 Trial
CANTON, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc.
09-26 04:52
Organogenesis Provides Update on Second Phase 3 ReNu® Study
Organogenesis Holdings Inc. remains confident in ReNu as a potential innovative therapy for managing knee osteoarthritis symptoms. The second Phase 3 trial of ReNu, a cryopreserved amniotic suspension allograft, showed a numerical improvement in baseline pain reduction over the first Phase 3 trial, despite not meeting the primary endpoint. The trial demonstrated a statistically significant maintenance of function (p<0.0001) and a favorable safety...
09-25 20:50
Organogenesis Holdings shares are trading lower after the company reported worse-than-expected Q2 financial results.
Organogenesis Holdings shares are trading lower after the company reported wors...
08-08 05:01
Organogenesis Holdings Narrows FY2025 Sales Guidance from $480.00M-$535.00M to $480.00M-$510.00M vs $477.80M Est
Organogenesis Holdings (NASDAQ:ORGO) narrows FY2025 sales outlook from $480.00 million-$535.00 million to $480.00 million-$510.00 million vs $477.80 million estimate.
08-08 04:28
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Cantor Fitzgerald Reiterates Overweight on Organogenesis Holdings, Maintains $7 Price Target
Cantor Fitzgerald analyst Ross Osborn reiterates Organogenesis Holdings (NASDAQ:ORGO) with a Overweight and maintains $7 price target.
07-15 20:46
